anlotinib + rituximab + gemcitabine + oxaliplatin

This combination, also known as A-RGEMOX, is a treatment regimen being investigated primarily for early relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The regimen combines anlotinib, an angiogenesis inhibitor, with the established R-GemOx (rituximab, gemcitabine, oxaliplatin) protocol that has shown efficacy in treating various lymphomas. ## Components and Mechanism The A-RGEMOX regimen consists of: - **Anlotinib**: An oral multi-target tyrosine kinase inhibitor that primarily targets angiogenesis pathways - **Rituximab**: A monoclonal antibody targeting CD20 on B cells - **Gemcitabine**: A nucleoside analog that disrupts DNA synthesis - **Oxaliplatin**: A platinum-based agent that forms DNA adducts and crosslinks The combination leverages potential synergistic effects between these agents. The R-GemOx portion (rituximab, gemcitabine, oxaliplatin) has already demonstrated efficacy in relapsed/refractory DLBCL with an acceptable toxicity profile[4][7]. The addition of anlotinib aims to enhance efficacy through anti-angiogenic effects. ## Clinical Development A-RGEMOX is currently being investigated in a Phase 2 clinical trial (NCT06086197) for early relapsed or refractory DLBCL[1]. The trial is recruiting patients with: - Diffuse Large B-cell Lymphoma that is recurrent - Diffuse Large B-cell Lymphoma that is refractory The dosing regimen in the trial includes: - Anlotinib: 12mg orally daily on days 1-14 - Rituximab: 375mg/m² on day 1 - Gemcitabine: 1000mg/m² on days 1 and 8 - Oxaliplatin: 130mg/m² on day 1 For patients aged 75 years or older, appropriate reduction of chemotherapy drugs (not less than 75% of the standard dose, or withdrawal of day 8 gemcitabine) may be implemented at the investigator's discretion[1]. ## Rationale and Background The R-GemOx regimen (without anlotinib) has been extensively studied and has shown promising results in treating relapsed/refractory DLBCL, particularly in elderly patients or those with comorbidities who are not candidates for high-dose therapy[2][4][5]. The regimen has demonstrated: - Consistent response rates in multicenter studies - Acceptable toxicity profile - Effectiveness in patients previously exposed to rituximab - Favorable safety profile compared to cisplatin-containing regimens, particularly regarding renal toxicity The addition of anlotinib to this established regimen is based on the hypothesis that combining an anti-angiogenic agent with chemotherapy may improve response rates in early relapsed/refractory DLBCL[1].